Seres Therapeutics, Inc. Total Assets

• Seres Therapeutics, Inc. showed a decrease of -1.2% in Total Assets from 2024 to 2025.
• This data is from Seres Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2015: $101.28 million | Q3 2015: $227.05 million | Q1 2016: $324.47 million | Q2 2016: $306.22 million | Q3 2016: $297.51 million | Q1 2017: $244.85 million | Q2 2017: $216.34 million | Q3 2017: $211.88 million | Q1 2018: $159.43 million | Q2 2018: $132.95 million | Q3 2018: $109.04 million | Q1 2019: $107.04 million | Q2 2019: $146.09 million | Q3 2019: $124.15 million | Q1 2020: $110.62 million | Q2 2020: $100.68 million | Q3 2020: $356.20 million | Q1 2021: $305.70 million | Q2 2021: $269.65 million | Q3 2021: $396.29 million | Q1 2022: $319.89 million | Q2 2022: $273.20 million | Q3 2022: $311.87 million | Q1 2023: $270.19 million | Q2 2023: $406.39 million | Q3 2023: $367.70 million | Q1 2024: $341.26 million | Q2 2024: $321.73 million | Q3 2024: $178.74 million | Q1 2025: $164.18 million | Q2 2025: $143.80 million | Q3 2025: $143.47 million.
• Over the full 12 years of available data (2014 to 2025), Seres Therapeutics, Inc.'s Total Assets has grown by 17.8%.
• Historical annual values: Fiscal year 2025: $138.19 million | Fiscal year 2024: $139.81 million | Fiscal year 2023: $358.60 million | Fiscal year 2022: $348.78 million | Fiscal year 2021: $354.86 million | Fiscal year 2020: $342.94 million | Fiscal year 2019: $132.44 million | Fiscal year 2018: $120.47 million | Fiscal year 2017: $189.52 million | Fiscal year 2016: $272.65 million | Fiscal year 2015: $216.90 million | Fiscal year 2014: $117.35 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026